Zhilong Wan

Title: Zhilong Wan: Innovator in ERK Inhibitors

Introduction

Zhilong Wan is a prominent inventor based in Beijing, China. He has made significant contributions to the field of pharmaceuticals, particularly in the development of ERK inhibitors. With a total of two patents to his name, his work is paving the way for advancements in cancer treatment.

Latest Patents

Zhilong Wan's latest patents focus on ERK inhibitors. The first patent presents a compound of Formula (I) or its pharmaceutically acceptable salts, esters, and prodrugs, which act as ERK2 inhibitors. This invention outlines a method for inhibiting ERK2 in patients requiring such treatment by administering an effective amount of the compound. Additionally, it provides a method for treating cancer in patients by using the same compound. The second patent also revolves around ERK inhibitors, detailing a pharmaceutical composition that includes an effective amount of the compound and a pharmaceutically acceptable carrier. This patent further describes a composition that combines the compound with other pharmaceutically active ingredients, such as chemotherapeutic agents.

Career Highlights

Throughout his career, Zhilong Wan has worked with notable companies, including Merck Sharp & Dohme Corporation and MSD R&D (China) Co., Ltd. His experience in these organizations has contributed to his expertise in pharmaceutical research and development.

Collaborations

Zhil